A multimodal atlas of tumour metabolism reveals the architecture of gene-metabolite covariation.


Journal

Nature metabolism
ISSN: 2522-5812
Titre abrégé: Nat Metab
Pays: Germany
ID NLM: 101736592

Informations de publication

Date de publication:
06 2023
Historique:
received: 22 11 2022
accepted: 09 05 2023
medline: 27 6 2023
pubmed: 20 6 2023
entrez: 19 6 2023
Statut: ppublish

Résumé

Tumour metabolism is controlled by coordinated changes in metabolite abundance and gene expression, but simultaneous quantification of metabolites and transcripts in primary tissue is rare. To overcome this limitation and to study gene-metabolite covariation in cancer, we assemble the Cancer Atlas of Metabolic Profiles of metabolomic and transcriptomic data from 988 tumour and control specimens spanning 11 cancer types in published and newly generated datasets. Meta-analysis of the Cancer Atlas of Metabolic Profiles reveals two classes of gene-metabolite covariation that transcend cancer types. The first corresponds to gene-metabolite pairs engaged in direct enzyme-substrate interactions, identifying putative genes controlling metabolite pool sizes. A second class of gene-metabolite covariation represents a small number of hub metabolites, including quinolinate and nicotinamide adenine dinucleotide, which correlate to many genes specifically expressed in immune cell populations. These results provide evidence that gene-metabolite covariation in cellularly heterogeneous tissue arises, in part, from both mechanistic interactions between genes and metabolites, and from remodelling of the bulk metabolome in specific immune microenvironments.

Identifiants

pubmed: 37337120
doi: 10.1038/s42255-023-00817-8
pii: 10.1038/s42255-023-00817-8
pmc: PMC10290959
doi:

Types de publication

Meta-Analysis Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1029-1044

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA252674
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA251543
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA276200
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27–47 (2016).
pubmed: 26771115 pmcid: 4715268 doi: 10.1016/j.cmet.2015.12.006
Zhang, J., Nuebel, E., Daley, G. Q., Koehler, C. M. & Teitell, M. A. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell 11, 589–595 (2012).
pubmed: 23122286 pmcid: 3492890 doi: 10.1016/j.stem.2012.10.005
Intlekofer, A. M. & Finley, L. W. S. Metabolic signatures of cancer cells and stem cells. Nat. Metab. 1, 177–188 (2019).
pubmed: 31245788 pmcid: 6594714 doi: 10.1038/s42255-019-0032-0
Fanciulli, M. et al. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of Lonidamine. Clin. Cancer Res. 6, 1590–1597 (2000).
Zhao, Y., Butler, E. B. & Tan, M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 4, e532 (2013).
pubmed: 23470539 pmcid: 3613838 doi: 10.1038/cddis.2013.60
Zhou, Y. et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res. 72, 304–314 (2012).
pubmed: 22084398 doi: 10.1158/0008-5472.CAN-11-1674
O’Sullivan, D., Sanin, D. E., Pearce, E. J. & Pearce, E. L. Metabolic interventions in the immune response to cancer. Nat. Rev. Immunol. 19, 324–335 (2019).
pubmed: 30820043 doi: 10.1038/s41577-019-0140-9
Hurley, H. J. et al. Frontline Science: AMPK regulates metabolic reprogramming necessary for interferon production in human plasmacytoid dendritic cells. J. Leukoc. Biol. 109, 299–308 (2021).
pubmed: 32640499 doi: 10.1002/JLB.3HI0220-130
Guerra, L., Bonetti, L. & Brenner, D. Metabolic modulation of immunity: a new concept in cancer immunotherapy. Cell Rep. 32, 107848 (2020).
pubmed: 32640218 doi: 10.1016/j.celrep.2020.107848
Domblides, C., Lartigue, L. & Faustin, B. Control of the antitumor immune response by cancer metabolism. Cells 8, 104 (2019).
pubmed: 30708988 pmcid: 6406288 doi: 10.3390/cells8020104
Ganeshan, K. & Chawla, A. Metabolic regulation of immune responses. Annu. Rev. Immunol. 32, 609–634 (2014).
pubmed: 24655299 pmcid: 5800786 doi: 10.1146/annurev-immunol-032713-120236
Anders, S. et al. Count-based differential expression analysis of RNA-sequencing data using R and Bioconductor. Nat. Protoc. 8, 1765–1786 (2013).
pubmed: 23975260 doi: 10.1038/nprot.2013.099
Penney, K. L. et al. Metabolomics of prostate cancer gleason score in tumor tissue and serum. Mol. Cancer Res. 19, 475–484 (2021).
pubmed: 33168599 doi: 10.1158/1541-7786.MCR-20-0548
Gentric, G. et al. PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers. Cell Metab. 29, 156–173 (2019).
pubmed: 30244973 pmcid: 6331342 doi: 10.1016/j.cmet.2018.09.002
Chaisaingmongkol, J. et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 32, 57–70 (2017).
pubmed: 28648284 pmcid: 5524207 doi: 10.1016/j.ccell.2017.05.009
Wang, L.-B. et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell 39, 509–528 (2021).
pubmed: 33577785 pmcid: 8044053 doi: 10.1016/j.ccell.2021.01.006
Calvo-Vidal, M. N. et al. Oncogenic HSP90 facilitates metabolic alterations in aggressive B cell lymphomas. Cancer Res. 81, 5202–5216 (2021).
pubmed: 34479963 pmcid: 8530929 doi: 10.1158/0008-5472.CAN-21-2734
Satoh, K. et al. Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proc. Natl Acad. Sci. USA 114, E7697–E7706 (2017).
pubmed: 28847964 pmcid: 5604037 doi: 10.1073/pnas.1710366114
Terunuma, A. et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J. Clin. Invest. 124, 398–412 (2014).
pubmed: 24316975 doi: 10.1172/JCI71180
Tang, X. et al. A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res. 16, 415 (2014).
pubmed: 25091696 pmcid: 4187326 doi: 10.1186/s13058-014-0415-9
Zhang, G. et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin. Cancer Res. 19, 4983–4993 (2013).
pubmed: 23918603 pmcid: 3778077 doi: 10.1158/1078-0432.CCR-13-0209
Hakimi, A. A. et al. An integrated metabolic atlas of clear-cell renal cell carcinoma. Cancer Cell 29, 104–116 (2016).
pubmed: 26766592 pmcid: 4809063 doi: 10.1016/j.ccell.2015.12.004
Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
pubmed: 13298683 doi: 10.1126/science.123.3191.309
Garcia-Bermudez, J. et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat. Cell Biol. 20, 775–781 (2018).
pubmed: 29941933 pmcid: 6030478 doi: 10.1038/s41556-018-0118-z
Krall, A. S. et al. Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth. Cell Metab. 33, 1013–1026 (2021).
pubmed: 33609439 pmcid: 8102379 doi: 10.1016/j.cmet.2021.02.001
Martínez-Reyes, I. et al. Mitochondrial ubiquinol oxidation is necessary for tumour growth. Nature 585, 288–292 (2020).
pubmed: 32641834 pmcid: 7486261 doi: 10.1038/s41586-020-2475-6
Sullivan, L. B. et al. Aspartate is an endogenous metabolic limitation for tumour growth. Nat. Cell Biol. 20, 782–788 (2018).
pubmed: 29941931 pmcid: 6051729 doi: 10.1038/s41556-018-0125-0
Labuschagne, C. F., van den Broek, N. J. F., Mackay, G. M., Vousden, K. H. & Maddocks, O. D. K. Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep. 7, 1248–1258 (2014).
pubmed: 24813884 doi: 10.1016/j.celrep.2014.04.045
Yang, M. & Vousden, K. H. Serine and one-carbon metabolism in cancer. Nat. Rev. Cancer 16, 650–662 (2016).
pubmed: 27634448 doi: 10.1038/nrc.2016.81
Puccetti, P. et al. Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. PLoS ONE 10, e0122046 (2015).
pubmed: 25881064 pmcid: 4400104 doi: 10.1371/journal.pone.0122046
Yaku, K., Okabe, K., Hikosaka, K. & Nakagawa, T. NAD metabolism in cancer therapeutics. Front. Oncol. 8, 622 (2018).
pubmed: 30631755 pmcid: 6315198 doi: 10.3389/fonc.2018.00622
Chiarugi, A., Dölle, C., Felici, R. & Ziegler, M. The NAD metabolome–a key determinant of cancer cell biology. Nat. Rev. Cancer 12, 741–752 (2012).
pubmed: 23018234 doi: 10.1038/nrc3340
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
doi: 10.1038/nature07385
Finlay, D. & Cantrell, D. A. Metabolism, migration and memory in cytotoxic T cells. Nat. Rev. Immunol. 11, 109–117 (2011).
pubmed: 21233853 pmcid: 3521506 doi: 10.1038/nri2888
Auslander, N. et al. A joint analysis of transcriptomic and metabolomic data uncovers enhanced enzyme–metabolite coupling in breast cancer. Sci. Rep. 6, 29662 (2016).
pubmed: 27406679 pmcid: 4942812 doi: 10.1038/srep29662
Li, H. et al. The landscape of cancer cell line metabolism. Nat. Med. 25, 850–860 (2019).
pubmed: 31068703 pmcid: 6629041 doi: 10.1038/s41591-019-0404-8
Therneau, T. M. & Grambsch, P. M. Modeling Survival Data: Extending the Cox Model (Springer New York, 2000); https://doi.org/10.1007/978-1-4757-3294-8
Badawy, A. A.-B. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int. J. Tryptophan Res. 10, 1178646917691938 (2017).
pubmed: 28469468 pmcid: 5398323 doi: 10.1177/1178646917691938
Chini, C. C. S. et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD
pubmed: 33199925 pmcid: 8752031 doi: 10.1038/s42255-020-00298-z
Hitchings, G. H. & Falco, E. A. The identification of guanine in extracts of Girella nigricans: the specificity of guanase. Proc. Natl Acad. Sci. USA 30, 294–297 (1944).
pubmed: 16578130 pmcid: 1078714 doi: 10.1073/pnas.30.10.294
Robinson, J. L. et al. An atlas of human metabolism. Sci. Signal. 13, eaaz1482 (2020).
pubmed: 32209698 pmcid: 7331181 doi: 10.1126/scisignal.aaz1482
Priolo, C. et al. Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma. Proc. Natl Acad. Sci. USA 115, E6274–E6282 (2018).
pubmed: 29891694 pmcid: 6142242 doi: 10.1073/pnas.1710849115
Long, Y. et al. Liver-specific overexpression of gamma-glutamyltransferase ameliorates insulin sensitivity of male C57BL/6 mice. J. Diabetes Res. 2017, 2654520 (2017).
pubmed: 28660214 pmcid: 5474247 doi: 10.1155/2017/2654520
Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282–288 (2021).
pubmed: 33828302 pmcid: 8122068 doi: 10.1038/s41586-021-03442-1
Zappasodi, R. et al. CTLA-4 blockade drives loss of T
pubmed: 33588426 pmcid: 8057670 doi: 10.1038/s41586-021-03326-4
Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009).
pubmed: 19847166 pmcid: 2783335 doi: 10.1038/nature08460
Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).
pubmed: 24113773 doi: 10.1038/ncomms3612
Kilgour, M. K. et al. 1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer. Sci. Adv. 7, eabe1174 (2021).
pubmed: 33523930 pmcid: 7817098 doi: 10.1126/sciadv.abe1174
Qian, B.-Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39–51 (2010).
pubmed: 20371344 pmcid: 4994190 doi: 10.1016/j.cell.2010.03.014
Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896 (2010).
pubmed: 20856220 doi: 10.1038/ni.1937
Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795 (2013).
pubmed: 24138885 doi: 10.1016/j.immuni.2013.10.003
Moffett, J. R. et al. Quinolinate as a marker for kynurenine metabolite formation and the unresolved question of NAD
pubmed: 32153556 pmcid: 7047773 doi: 10.3389/fimmu.2020.00031
Rappez, L. et al. SpaceM reveals metabolic states of single cells. Nat. Methods 18, 799–805 (2021).
pubmed: 34226721 pmcid: 7611214 doi: 10.1038/s41592-021-01198-0
Fuhrer, T., Zampieri, M., Sévin, D. C., Sauer, U. & Zamboni, N. Genomewide landscape of gene-metabolome associations in Escherichia coli. Mol. Syst. Biol. 13, 907 (2017).
pubmed: 28093455 pmcid: 5293155 doi: 10.15252/msb.20167150
Mülleder, M. et al. Functional metabolomics describes the yeast biosynthetic regulome. Cell 167, 553–565 (2016).
pubmed: 27693354 pmcid: 5055083 doi: 10.1016/j.cell.2016.09.007
Navas, L. E. & Carnero, A. NAD
pubmed: 33384409 pmcid: 7775471 doi: 10.1038/s41392-020-00354-w
Taylor, M. J., Lukowski, J. K. & Anderton, C. R. Spatially resolved mass spectrometry at the single cell: recent innovations in proteomics and metabolomics. J. Am. Soc. Mass Spectrom. 32, 872–894 (2021).
pubmed: 33656885 pmcid: 8033567 doi: 10.1021/jasms.0c00439
Abbas, I. et al. Kidney lipidomics by mass spectrometry imaging: a focus on the glomerulus. Int. J. Mol. Sci. 20, 1623 (2019).
pubmed: 30939806 pmcid: 6480965 doi: 10.3390/ijms20071623
Sun, N. et al. Mass spectrometry imaging establishes 2 distinct metabolic phenotypes of aldosterone-producing cell clusters in primary aldosteronism. Hypertension 75, 634–644 (2020).
pubmed: 31957522 doi: 10.1161/HYPERTENSIONAHA.119.14041
Basu, S. S. et al. Rapid MALDI mass spectrometry imaging for surgical pathology. NPJ Precis. Oncol. 3, 17 (2019).
pubmed: 31286061 pmcid: 6609678 doi: 10.1038/s41698-019-0089-y
Chang, M. T. et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 8, 174–183 (2018).
pubmed: 29247016 doi: 10.1158/2159-8290.CD-17-0321
Findlay, G. M. et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature 562, 217–222 (2018).
pubmed: 30209399 pmcid: 6181777 doi: 10.1038/s41586-018-0461-z
Nilsson, R. et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat. Commun. 5, 3128 (2014).
pubmed: 24451681 doi: 10.1038/ncomms4128
Gatto, F., Nookaew, I. & Nielsen, J. Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear-cell renal carcinoma. Proc. Natl Acad. Sci. USA 111, E866–E875 (2014).
pubmed: 24550497 pmcid: 3948310 doi: 10.1073/pnas.1319196111
Hu, J. et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 31, 522–529 (2013).
pubmed: 23604282 pmcid: 3681899 doi: 10.1038/nbt.2530
Carvalho, B. S. & Irizarry, R. A. A framework for oligonucleotide microarray preprocessing. Bioinformatics 26, 2363–2367 (2010).
pubmed: 20688976 pmcid: 2944196 doi: 10.1093/bioinformatics/btq431
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. Bioinformatics 28, 2184–2185 (2012).
pubmed: 22743226 doi: 10.1093/bioinformatics/bts356
Lawrence, M. et al. Software for computing and annotating genomic ranges. PLoS Comput. Biol. 9, e1003118 (2013).
pubmed: 23950696 pmcid: 3738458 doi: 10.1371/journal.pcbi.1003118
Harrow, J. et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 22, 1760–1774 (2012).
pubmed: 22955987 pmcid: 3431492 doi: 10.1101/gr.135350.111
Harrow, J. et al. GENCODE: producing a reference annotation for ENCODE. Genome Biol. https://doi.org/10.1186/gb-2006-7-s1-s4 (2006).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Dieterle, F., Ross, A., Schlotterbeck, G. & Senn, H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in
pubmed: 16808434 doi: 10.1021/ac051632c
Wishart, D. S. et al. HMDB: the human metabolome database. Nucleic Acids Res. 35, D521–D526 (2007).
pubmed: 17202168 pmcid: 1899095 doi: 10.1093/nar/gkl923
Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27–30 (2000).
pubmed: 10592173 pmcid: 102409 doi: 10.1093/nar/28.1.27
Therneau, T. M. A Package for survival analysis in R. https://CRAN.R-project.org/package=survival (2022).
Newson, R. Parameters behind ‘nonparametric’ statistics: Kendall’s tau, Somers’ D and median differences. Stata J. 2, 45–64 (2002).
doi: 10.1177/1536867X0200200103
Therneau, T. M. & Watson, D. A. The concordance statistic and the Cox model. Tech. Rep. 85, 1–18 (2017).
Newson, R. Confidence intervals for rank statistics: Somers’ D and extensions. Stata J. 6, 309–334 (2006).
doi: 10.1177/1536867X0600600302
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289–300 (1995).
Reimand, J. et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat. Protoc. 14, 482–517 (2019).
pubmed: 30664679 pmcid: 6607905 doi: 10.1038/s41596-018-0103-9
Kolde, R. CRAN—package pheatmap. https://cran.r-project.org/web/packages/pheatmap/index.html (2019).
Yoshihara, K., Kim, H. & Verhaak, R. G. ESTIMATE: estimate of stromal and immune cells in malignant tumor tissues from expression data. https://r-forge.r-project.org/projects/estimate/ (2016).
Ganly, I. et al. Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma. Sci. Adv. 8, eabn9699 (2022).
pubmed: 35731870 pmcid: 9216518 doi: 10.1126/sciadv.abn9699
Han, Y. et al. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. https://doi.org/10.1093/nar/gkac959/ (2022).
Sun, D. et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 49, D1420–D1430 (2021).
pubmed: 33179754 doi: 10.1093/nar/gkaa1020

Auteurs

Elisa Benedetti (E)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Institute of Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.

Eric Minwei Liu (EM)

Computational Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Cerise Tang (C)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Computational Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Fengshen Kuo (F)

Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Mustafa Buyukozkan (M)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Institute of Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.

Tricia Park (T)

Computational Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jinsung Park (J)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Fabian Correa (F)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

A Ari Hakimi (AA)

Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Andrew M Intlekofer (AM)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jan Krumsiek (J)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA. jak2043@med.cornell.edu.
Institute of Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA. jak2043@med.cornell.edu.
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA. jak2043@med.cornell.edu.

Ed Reznik (E)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA. reznike@mskcc.org.
Computational Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. reznike@mskcc.org.
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. reznike@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH